Direct Oral Anticoagulants for Stroke Prevention in Special Populations: Beyond the Clinical Trials

Currently, direct oral anticoagulants (DOACs) are the first-line anticoagulant strategy in patients with non-valvular atrial fibrillation (NVAF). They are characterized by a more favorable pharmacological profile than warfarin, having demonstrated equal efficacy in stroke prevention and greater safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Carbone, Andreina, Bottino, Roberta, D’Andrea, Antonello, Russo, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856013/
https://www.ncbi.nlm.nih.gov/pubmed/36672639
http://dx.doi.org/10.3390/biomedicines11010131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856013/
https://www.ncbi.nlm.nih.gov/pubmed/36672639
http://dx.doi.org/10.3390/biomedicines11010131

Ejemplares similares